Meanwhile, there was bad blood between cell therapy players and their investors.
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.
In oncology settings outside multiple myeloma investors have picked two early winners.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.